Sildenafil Citrate is a PDE5 inhibitor indicated for erectile dysfunction and pulmonary arterial hypertension. We supply it to US manufacturers of tablets, oral suspension and injection.
Data from PubChem (CID 135413523) and FDA’s substance registry
CAS number
171599-83-0
Molecular formula
C28H38N6O11S
Molecular weight
666.7g/mol
FDA UNII
IUPAC name
5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,5-d]pyrimidin-7-one;2-hydroxypropane-1,2,3-tricarboxylic acid
InChIKey
DEIYFTQMQPDXOT-UHFFFAOYSA-N
- Appearance
- White to off-white crystalline powder.
- Solubility
- Solubility in water is 3.5 mg/mL.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Strengths are expressed as sildenafil base. The same API goes into erectile dysfunction tablets and the 20 mg tablets for pulmonary arterial hypertension.
On the US market
- Reference product
- ViagraNDA 020895
- Approved ANDAs
- 38 with a marketed product
- Approved forms and strengths
- Tablet 20 mg, 25 mg, 50 mg, 100 mg
- Powder for oral suspension 10 mg/mL
- Oral film 25 mg, 50 mg, 75 mg, 100 mg
- Injection 10 mg/12.5 mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com